Filtered By:
Specialty: Cancer & Oncology
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 124123 results found since Jan 2013.
Strict self-isolation did not protect Swedish cancer patients on active treatment from the risk of becoming seropositive for SARS-CoV-2
Conclusion: For Swedish patients on active cancer treatment, high self-assessed COVID-19-related anxiety or strict adherence to self-isolation guidelines were not associated with a lower risk of COVID-19. Patients with HM were less likely to develop serological antibody response after COVID-19 and were more likely to require advanced hospital care, but expressed less COVID-19-related anxiety than patients with SM.PMID:37729083 | DOI:10.1080/0284186X.2023.2257873
Source: Acta Oncologica - September 20, 2023 Category: Cancer & Oncology Authors: Beatrice Ginman Simon Pahnke Eva Freyhult Tove Hoffman Linda Kolstad Bengt R önnberg Åke Lundkvist Kerstin Hamberg Levedahl Gunilla Enblad Ingrid Glimelius Source Type: research
Cancers, Vol. 15, Pages 4651: Is Insulin Receptor Substrate4 (IRS4) a Platform Involved in the Activation of Several Oncogenes?
Miguel A. Ortega
The IRS (insulin receptor substrate) family of scaffold proteins includes insulin receptor substrate-4 (IRS4), which is expressed only in a few cell lines, including human kidney, brain, liver, and thymus and some cell lines. Its N-terminus carries a phosphotyrosine-binding (PTB) domain and a pleckstrin homology domain (PH), which distinguishes it as a member of this family. In this paper, we collected data about the molecular mechanisms that explain the relevance of IRS4 in the development of cancer and identify IRS4 differences that distinguish it from IRS1 and IRS2. Search engines and different dat...
Source: Cancers - September 20, 2023 Category: Cancer & Oncology Authors: Luis G. Guijarro Francisco Javier Justo Bermejo Diego Liviu Boaru Patricia De Castro-Martinez Diego De Leon-Oliva Oscar Fraile-Mart ínez Cielo Garcia-Montero Melchor Alvarez-Mon Mar ía del Val Toledo-Lobo Miguel A. Ortega Tags: Review Source Type: research
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models
We present a comprehensive therapeutic and biomarker analysis of a B7H3-ADC with pyrrolobenzodiazepine(PBD) payload in 26 treatment-resistant, metastatic prostate cancer(mPC) models. B7H3 is a tumor-specific surface protein widely expressed in mPC, and PBD is a DNA cross-linking agent. B7H3 expression was necessary but not sufficient for B7H3-PBD-ADC responsiveness. RB1 deficiency and/or replication stress, characteristics of poor prognosis, conferred sensitivity and were associated with complete tumor regression in both neuroendocrine (NEPC) and androgen receptor positive(ARPC) prostate cancer models, even with low B7H3 l...
Source: Clinical Prostate Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Supreet Agarwal Lei Fang Kerry McGowen JuanJuan Yin Joel Bowman Anson T Ku Aian Neil Alilin Eva Corey Martine P Roudier Lawrence D True Ruth F Dumpit Ilsa Coleman John K Lee Peter S Nelson Brian J Capaldo Aida Mariani Clare E Hoover Ilya S Senatorov Micha Source Type: research
Clinical utility of inflammatory and nutritious index as therapeutic prediction of nivolumab plus ipilimumab in advanced NSCLC
CONCLUSION: The NLR, PLR, SII, PNI, ALI, and GPS were significantly associated with the outcome of Nivo-Ipi treatment in patients with NSCLC. The PNI was the most suitable marker regardless of histological type. The SII and PNI were the most promising markers for patients with and without PD-L1 expression, respectively.PMID:37725914 | DOI:10.1159/000534169
Source: Oncology - September 19, 2023 Category: Cancer & Oncology Authors: Ou Yamaguchi Kyoichi Kaira Hisao Imai Atsuto Mouri Ayako Shiono Yu Miura Kosuke Hashimoto Kunihiko Kobayashi Hiroshi Kagamu Source Type: research
Clinical implication of CDH1 mutations in genetic testing for diffuse gastric cancer patients
CONCLUSIONS: We conclude that germline CDH1 genetic testing is indicated only in families meeting the clinical criteria for the HDGC syndrome. This observation suggests that clinical phenotypes that do not clearly fulfill these criteria should not be considered for CDH1 genetic testing.PMID:37725907 | DOI:10.1159/000533774
Source: Oncology - September 19, 2023 Category: Cancer & Oncology Authors: Giovanni Corso Cristina Maria Trovato Salvatore Petitto Antonia Girardi Alessandra Margherita De Scalzi Beatrice Bianchi Francesca Magnoni Antonio Cioffi Viviana Galimberti Paolo Veronesi Giovanni Mazzarol Patrick Maisonneuve Source Type: research
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
CONCLUSION: A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.PMID:37725049 | DOI:10.1093/oncolo/oyad258
Source: The Oncologist - September 19, 2023 Category: Cancer & Oncology Authors: Juan Luis Gomez Marti Azadeh Nasrazadani Ying Ding Daniel Normolle Adam M Brufsky Source Type: research
Proteomic landscape of primary and metastatic brain tumors for heterogeneity discovery
CONCLUSIONS AND CLINICAL RELEVANCE: We characterized an extensive proteomic landscape of BrMs and gliomas. These findings have promising implications for the development of targeted therapies for BrMs and gliomas.PMID:37726528 | DOI:10.1002/prca.202300010
Source: Clinical Lung Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Shuang Yang Chengbin Zhou Lei Zhang Yueting Xiong Yongtao Zheng Liuguan Bian Xiaohui Liu Source Type: research
Distinct Features of Plasma Ultrashort Single-Stranded Cell-Free DNA as Biomarkers for Lung Cancer Detection
CONCLUSIONS: These observations indicate that the distinct biological processes of uscfDNA and that FE peaks, fragmentomics, end-motifs, and G-Quad signatures are uscfDNA features with promising biomarker potential. These findings further justify its exploration as a distinct class of biomarker to augment pre-existing liquid biopsy approaches.PMID:37725931 | DOI:10.1093/clinchem/hvad131
Source: Clinical Lung Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Jordan Cheng Neeti Swarup Feng Li Misagh Kordi Chien-Chung Lin Szu-Chun Yang Wei-Lun Huang Mohammad Aziz Yong Kim David Chia Yu-Min Yeh Fang Wei David Zheng Liying Zhang Matteo Pellegrini Wu-Chou Su David T W Wong Source Type: research
Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair
CONCLUSIONS: In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increase the therapeutic success.PMID:37725585 | DOI:10.1158/1078-0432.CCR-23-1795
Source: Clinical Lung Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Anna Solta Kristiina Boettiger Ildik ó Kovács Christian Lang Zsolt Megyesfalvi Franziska Ferk Miroslav Mi šík Konrad Hoetzenecker Clemens Aigner Christian R Kowol Siegfried Knasmueller Michael Grusch Be áta Szeitz Melinda Rezeli Balazs Dome Karin Sch Source Type: research
Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence
CONCLUSIONS: This work suggests a potential benefit for combining senolytics with immunotherapy in older patients with GBM.PMID:37725593 | DOI:10.1158/1078-0432.CCR-23-0834
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Margaret Johnson April Bell Kristen L Lauing Erik Ladomersky Lijie Zhai Manon Penco-Campillo Yajas Shah Elizabeth Mauer Joanne Xiu Theodore Nicolaides Michael Drumm Kathleen McCortney Olivier Elemento Miri Kim Prashant Bommi Justin T Low Ruba Memon Jennif Source Type: research
Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair
CONCLUSIONS: In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increase the therapeutic success.PMID:37725585 | DOI:10.1158/1078-0432.CCR-23-1795
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Anna Solta Kristiina Boettiger Ildik ó Kovács Christian Lang Zsolt Megyesfalvi Franziska Ferk Miroslav Mi šík Konrad Hoetzenecker Clemens Aigner Christian R Kowol Siegfried Knasmueller Michael Grusch Be áta Szeitz Melinda Rezeli Balazs Dome Karin Sch Source Type: research
Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma
CONCLUSIONS: Refractory T-ALL has not been fully characterized. Alterations in PDGFRA or other targetable kinases may inform therapy for patients with refractory T-ALL who otherwise have limited treatment options. Clinical genomic profiling, in real time, is needed for fully informed therapeutic decision making.PMID:37725576 | DOI:10.1158/1078-0432.CCR-22-2562
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Jonathan Paolino Boris Dimitrov Beth Apsel Winger Angelica Sandoval-Perez Amith Vikram Rangarajan Nicole Ocasio-Martinez Harrison K Tsai Yuting Li Amanda L Robichaud Delan Khalid Charlie Hatton Riaz Gillani Petri Polonen Anthony Dilig Giacomo Gotti Julia Source Type: research
Novel clinical trial designs with dose optimization to improve long-term outcomes
Clin Cancer Res. 2023 Sep 19. doi: 10.1158/1078-0432.CCR-23-2222. Online ahead of print.ABSTRACTConventional designs for choosing a dose for a new therapy may select doses that are unsafe or ineffective, and fail to optimize progression free survival time, overall survival time, or remission duration. We explain and illustrate limitations of conventional dose finding designs, and make four recommendations to address these problems. When feasible, a dose-finding design should account for long-term outcomes, include screening rules that drop unsafe or ineffective doses, enroll an adequate sample size, and randomize patients ...
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Peter F Thall Yong Zang Andrew G Chapple Ying Yuan Ruitao Lin David Marin Pavlos Msaouel Source Type: research
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial
CONCLUSIONS: We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.PMID:37725572 | DOI:10.1158/1078-0432.CCR-23-1801
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Theresa Link Jens-Uwe Blohmer Wolfgang D Schmitt Jan Dominik Kuhlmann Marianne Just Michael Untch Oliver Stotzer Peter A Fasching Marc Thill Mattea Reinisch Andreas Schneeweiss Pauline Wimberger Sabine Seiler Jens Huober Christian Jackisch Kerstin Rhiem C Source Type: research
Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-associated Immunity in Lynch Syndrome
CONCLUSIONS: Together these data have important implications for cancer interception in LS, and document for the first-time biological effects of exercise in the immune system of a target organ in patients at-risk for cancer.PMID:37724990 | DOI:10.1158/1078-0432.CCR-23-0088
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Nan Deng Laura Reyes-Uribe Johannes F Fahrmann Whittney S Thoman Mark F Munsell Jennifer B Dennison Eunice Murage Ranran Wu Ernest T Hawk Selvi Thirumurthi Patrick M Lynch Christina M Dieli-Conwright Alexander J Lazar Sonali Jindal Khoi Chu Manoj Chelvana Source Type: research
